{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:05:42Z","timestamp":1744149942849},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1007\/s11936-004-0015-6","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T13:10:55Z","timestamp":1180876255000},"page":"61-68","source":"Crossref","is-referenced-by-count":4,"title":["Diastolic dysfunction"],"prefix":"10.1007","volume":"6","author":[{"given":"Sean W.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"15_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0735-1097(97)00144-7","volume":"30","author":"RA Nishimura","year":"1997","unstructured":"Nishimura RA, Tajik AJ: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography in the clinician\u2019s Rosetta Stone. J Am Coll Cardiol 1997, 30:8\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","volume":"289","author":"MM Redfield","year":"2003","unstructured":"Redfield MM, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194\u2013202. Provides a good estimate of the prevalence of diastolic dysfunction, diagnosed with rigorous echocardiographic criteria, in the community setting. Also provides some data on the prognosis of this disease.","journal-title":"JAMA"},{"key":"15_CR3","unstructured":"American College of Cardiology: ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult. http:\/\/www.acc.org\/clinical\/guidelines\/ failure\/hf_index.htm. Accessed September 1, 2003. Key guidelines for the management of heart failure, including diastolic heart failure."},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/hc1102.105289","volume":"105","author":"MR Zile","year":"2002","unstructured":"Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, measurements of diastolic dysfunction. Circulation 2002, 105:1387\u20131393.","journal-title":"Circulation"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0735-1097(03)00186-4","volume":"41","author":"MR Zile","year":"2003","unstructured":"Zile MR: Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003, 41:1519\u20131522.","journal-title":"J Am Coll Cardiol"},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/hc1202.105290","volume":"105","author":"MR Zile","year":"2002","unstructured":"Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002, 105:1503\u20131508.","journal-title":"Circulation"},{"key":"15_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1525-139X.2003.16033.x","volume":"16","author":"SW Murphy","year":"2003","unstructured":"Murphy SW: Management of heart failure and coronary artery disease in patients with chronic kidney disease. Semin Dial 2003, 16:165\u2013172.","journal-title":"Semin Dial"},{"key":"15_CR8","doi-asserted-by":"crossref","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial of beta-blockade in heart failure. CIBIS Investigators and Committees [no authors listed]. Lancet 1999, 353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"15_CR9","doi-asserted-by":"crossref","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure. Metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group [no authors listed]. Lancet 1999, 353:2001\u20132007.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1013745705318","volume":"7","author":"DW Kitzman","year":"2002","unstructured":"Kitzman DW: Diastolic heart failure in the elderly. Heart Fail Rev 2002, 7:17\u201327.","journal-title":"Heart Fail Rev"},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","volume":"335","author":"M Packer","year":"1996","unstructured":"Packer M, O\u2019Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107\u20131114.","journal-title":"N Engl J Med"},{"key":"15_CR12","doi-asserted-by":"crossref","unstructured":"The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:525\u2013533.","DOI":"10.1056\/NEJM199702203360801"},{"key":"15_CR13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003, 362:777\u2013781. A large, randomized controlled study of the ARB candesartan specifically in patients with ejection fraction greater than 40%.","journal-title":"Lancet"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.0000053948.10914.49","volume":"107","author":"BG Angeja","year":"2003","unstructured":"Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107:659\u2013663.","journal-title":"Circulation"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0735-1097(95)00503-X","volume":"27","author":"P Carson","year":"1996","unstructured":"Carson P, Johnson G, Fletcher R, et al.: Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics, prognosis, and response to therapy in the vasodilator in heart failure trials (V-HeFT). J Am Coll Cardiol 1996, 27:642\u2013649.","journal-title":"J Am Coll Cardiol"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000176668","volume":"85","author":"SV Eriksson","year":"1994","unstructured":"Eriksson SV, Kjekshus J, Offstad J, et al.: Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. Cardiology 1994, 85:137\u2013144.","journal-title":"Cardiology"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9149(93)90520-M","volume":"71","author":"WS Aronow","year":"1993","unstructured":"Aronow WS, Kronzon I: Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993, 71:602\u2013604.","journal-title":"Am J Cardiol"},{"issue":"suppl A","key":"15_CR18","first-page":"245","volume":"2","author":"EF Philbin","year":"1997","unstructured":"Philbin EF, Erb T, Jenkins P: The natural history of heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 1997, 2(suppl A):245.","journal-title":"J Am Coll Cardiol"},{"key":"15_CR19","doi-asserted-by":"crossref","unstructured":"Effects of an angiotensin converting enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Study Investigators [no authors listed]. N Engl J Med 2000, 342:145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"15_CR20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/jama.283.15.2013","volume":"283","author":"L Lasagna","year":"2000","unstructured":"Lasagna L: Diuretics vs adrenergic blockers for treatment of hypertension. JAMA 2000, 283:2013\u20132014.","journal-title":"JAMA"},{"key":"15_CR21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","volume":"108","author":"PM Okin","year":"2003","unstructured":"Okin PM, Devereux RB, Jern S, et al.: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003, 108:684\u2013690.","journal-title":"Circulation"},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003.","journal-title":"Lancet"},{"key":"15_CR23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(99)00048-0","volume":"33","author":"JG Warner","year":"1999","unstructured":"Warner JG, Metzeger C, Kitzman DW, et al.: Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999, 33:1567\u20131572.","journal-title":"J Am Coll Cardiol"},{"key":"15_CR24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARMadded trial. Lancet 2003, 362:767\u2013771.","journal-title":"Lancet"},{"key":"15_CR25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/hy1101.099484","volume":"38","author":"F Zannad","year":"2001","unstructured":"Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering with the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227\u20131232.","journal-title":"Hypertension"},{"key":"15_CR26","doi-asserted-by":"crossref","unstructured":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) [no authors listed]. Am J Cardiol 1996, 78:902\u2013907.","DOI":"10.1016\/S0002-9149(96)00465-1"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-004-0015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-004-0015-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-004-0015-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:30Z","timestamp":1559436750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-004-0015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11936-004-0015-6","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}